Logo image of OCI.AS

OCI NV (OCI.AS) Stock Fundamental Analysis

AMS:OCI - Euronext Amsterdam - NL0010558797 - Common Stock - Currency: EUR

11.21  +0.16 (+1.45%)

Fundamental Rating

2

OCI gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 61 industry peers in the Chemicals industry. OCI may be in some trouble as it scores bad on both profitability and health. OCI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

OCI had negative earnings in the past year.
In the past year OCI had a positive cash flow from operations.
In multiple years OCI reported negative net income over the last 5 years.
OCI had a positive operating cash flow in each of the past 5 years.
OCI.AS Yearly Net Income VS EBIT VS OCF VS FCFOCI.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B

1.2 Ratios

The Return On Assets of OCI (-5.57%) is worse than 63.49% of its industry peers.
OCI has a Return On Equity of -54.32%. This is in the lower half of the industry: OCI underperforms 79.37% of its industry peers.
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROIC N/A
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A
OCI.AS Yearly ROA, ROE, ROICOCI.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40

1.3 Margins

OCI has a worse Gross Margin (2.10%) than 80.95% of its industry peers.
The Profit Margin and Operating Margin are not available for OCI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 2.1%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCI.AS Yearly Profit, Operating, Gross MarginsOCI.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

3

2. Health

2.1 Basic Checks

OCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OCI remains at a similar level compared to 1 year ago.
Compared to 5 years ago, OCI has more shares outstanding
The debt/assets ratio for OCI has been reduced compared to a year ago.
OCI.AS Yearly Shares OutstandingOCI.AS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
OCI.AS Yearly Total Debt VS Total AssetsOCI.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B 8B

2.2 Solvency

Based on the Altman-Z score of 0.21, we must say that OCI is in the distress zone and has some risk of bankruptcy.
OCI's Altman-Z score of 0.21 is on the low side compared to the rest of the industry. OCI is outperformed by 79.37% of its industry peers.
OCI has a debt to FCF ratio of 44.52. This is a negative value and a sign of low solvency as OCI would need 44.52 years to pay back of all of its debts.
With a Debt to FCF ratio value of 44.52, OCI perfoms like the industry average, outperforming 42.86% of the companies in the same industry.
OCI has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
OCI has a Debt to Equity ratio of 2.03. This is amonst the worse of the industry: OCI underperforms 87.30% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Altman-Z 0.21
ROIC/WACCN/A
WACC6.08%
OCI.AS Yearly LT Debt VS Equity VS FCFOCI.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B 2B 3B 4B

2.3 Liquidity

OCI has a Current Ratio of 1.39. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.39, OCI is doing worse than 65.08% of the companies in the same industry.
OCI has a Quick Ratio of 1.37. This is a normal value and indicates that OCI is financially healthy and should not expect problems in meeting its short term obligations.
OCI's Quick ratio of 1.37 is fine compared to the rest of the industry. OCI outperforms 68.25% of its industry peers.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.37
OCI.AS Yearly Current Assets VS Current LiabilitesOCI.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2B 4B 6B

More info and screens

1

3. Growth

3.1 Past

The earnings per share for OCI have decreased strongly by -123.19% in the last year.
Looking at the last year, OCI shows a very negative growth in Revenue. The Revenue has decreased by -63.19% in the last year.
OCI shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -9.61% yearly.
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%

3.2 Future

Based on estimates for the next years, OCI will show a very strong growth in Earnings Per Share. The EPS will grow by 26.31% on average per year.
Based on estimates for the next years, OCI will show a very negative growth in Revenue. The Revenue will decrease by -15.65% on average per year.
EPS Next Y91.45%
EPS Next 2Y60.43%
EPS Next 3Y43.32%
EPS Next 5Y26.31%
Revenue Next Year-51.36%
Revenue Next 2Y-31.7%
Revenue Next 3Y-20.51%
Revenue Next 5Y-15.65%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
OCI.AS Yearly Revenue VS EstimatesOCI.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
OCI.AS Yearly EPS VS EstimatesOCI.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 4 6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

OCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 27.43, the valuation of OCI can be described as expensive.
The rest of the industry has a similar Price/Forward Earnings ratio as OCI.
OCI's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 22.10.
Industry RankSector Rank
PE N/A
Fwd PE 27.43
OCI.AS Price Earnings VS Forward Price EarningsOCI.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of OCI is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 47.73
EV/EBITDA N/A
OCI.AS Per share dataOCI.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

OCI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
OCI's earnings are expected to grow with 43.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y60.43%
EPS Next 3Y43.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCI NV

AMS:OCI (3/7/2025, 7:00:00 PM)

11.21

+0.16 (+1.45%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-12 2024-11-12
Earnings (Next)03-14 2025-03-14/amc
Inst Owners32.2%
Inst Owner ChangeN/A
Ins Owners8.71%
Ins Owner ChangeN/A
Market Cap2.37B
Analysts80
Price Target16.31 (45.5%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend4.31
Dividend Growth(5Y)N/A
DP-34.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)486.8%
Min EPS beat(2)232.01%
Max EPS beat(2)741.58%
EPS beat(4)2
Avg EPS beat(4)85.49%
Min EPS beat(4)-492.57%
Max EPS beat(4)741.58%
EPS beat(8)3
Avg EPS beat(8)31.49%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)37.56%
Min Revenue beat(2)20.15%
Max Revenue beat(2)54.98%
Revenue beat(4)2
Avg Revenue beat(4)8.41%
Min Revenue beat(4)-23.05%
Max Revenue beat(4)54.98%
Revenue beat(8)5
Avg Revenue beat(8)21.58%
Revenue beat(12)9
Avg Revenue beat(12)32.19%
Revenue beat(16)12
Avg Revenue beat(16)36.43%
PT rev (1m)1.91%
PT rev (3m)1.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-515.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-4.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 27.43
P/S 0.64
P/FCF 47.73
P/OCF 4.65
P/B 2.79
P/tB 2.96
EV/EBITDA N/A
EPS(TTM)-0.44
EYN/A
EPS(NY)0.41
Fwd EY3.65%
FCF(TTM)0.23
FCFY2.1%
OCF(TTM)2.41
OCFY21.5%
SpS17.6
BVpS4.01
TBVpS3.78
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.57%
ROE -54.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 2.1%
FCFM 1.33%
ROA(3y)4.7%
ROA(5y)1.72%
ROE(3y)13.16%
ROE(5y)-0.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 2.03
Debt/FCF 44.53
Debt/EBITDA N/A
Cap/Depr -4159.17%
Cap/Sales 12.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.37
Altman-Z 0.21
F-Score4
WACC6.08%
ROIC/WACCN/A
Cap/Depr(3y)123.26%
Cap/Depr(5y)93.86%
Cap/Sales(3y)13.94%
Cap/Sales(5y)11.86%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-123.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%164.52%
EPS Next Y91.45%
EPS Next 2Y60.43%
EPS Next 3Y43.32%
EPS Next 5Y26.31%
Revenue 1Y (TTM)-63.19%
Revenue growth 3Y-17.33%
Revenue growth 5Y-9.61%
Sales Q2Q%-11.72%
Revenue Next Year-51.36%
Revenue Next 2Y-31.7%
Revenue Next 3Y-20.51%
Revenue Next 5Y-15.65%
EBIT growth 1Y-116.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.37%
EBIT Next 3Y6.31%
EBIT Next 5Y-0.48%
FCF growth 1Y-98.26%
FCF growth 3Y-23.28%
FCF growth 5Y-15.81%
OCF growth 1Y-83.68%
OCF growth 3Y4.02%
OCF growth 5Y0.7%